We treated tumor-bearing mice with anti-CD3, anti-CD4, or anti-CD8 antibodies and found that neutralization of CD3+, CD8+, or CD4+ T cells indeed attenuated the tumor growth inhibition induced by Prmt3-KO (Supplementary Fig. 6A–F). The gene discussed is PRMT3; the disease is neoplasm.